Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Therapeutic Implications
No Thumbnail Available
Date
2025
Journal Title
Journal ISSN
Volume Title
Publisher
Pharmaceuticals
Abstract
Hepatocellular carcinoma (HCC), the most prevalent primary liver cancer, continues to
pose a significant global health burden due to its high mortality rate. In addition to genetic
alterations, epigenetic aberrations, including DNA methylation, histone modifications,
chromatin remodeling, and noncoding RNA (ncRNA) dysregulation, play critical roles in
HCCinitiation and progression. Notably, miR-375 and miR-483-5p are among the most
dysregulated miRNAs in HCC, with their altered expression levels closely associated with
tumor stage and patient survival. These epigenetic modifications offer promising therapeu
tic avenues due to their reversibility and dynamic nature. Furthermore, specific epigenetic
signatures such as CDH1 promoter hypermethylation and HOTAIR overexpression are
being explored as potential biomarkers for early detection and treatment response. In this
chapter, we review recent advances in the epigenetic landscape of HCC and discuss their
diagnostic and therapeutic implications, highlighting their potential to improve patient
outcomes through personalized medicine approaches
Description
Keywords
DNA methylation, epigenetics, histone methylation, liver damage, ncRNAs (noncoding ribonucleic acid)
